01:54 PM EST, 01/07/2025 (MT Newswires) -- Citius Pharmaceuticals' ( CTXR ) shares were up more than 7% in recent Tuesday trading after the company and its Citius Oncology unit announced plans to launch Lymphir commercially in the first half of 2025.

Lymphir is an immunotherapy for adults with relapsed or refractory cutaneous T-cell lymphoma.

The companies said they have made progress in key launch areas, including securing commercial supply agreements, producing first-year launch supply, developing a patient assistance program, and working on reimbursement pathways.

Price: 4.22, Change: +0.31, Percent Change: +7.80